IDENIX PHARMACEUTICALS INC 4
4 · IDENIX PHARMACEUTICALS INC · Filed Aug 5, 2014
Insider Transaction Report
Form 4
Dumas Jacques
EVP, Chief Scientific Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−250,000→ 0 totalExercise: $7.42Exp: 2024-01-19→ Common Stock (250,000 underlying)
Footnotes (1)
- [F1]These options, which vested in 48 equal monthly installments beginning on January 31, 2014, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. in exchange for a cash payment of $17.08 per share, representing the difference between the exercise price of the options and $24.50 per share.